146 related articles for article (PubMed ID: 18479214)
1. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease?
Hutchison CA; Cockwell P; Harding S; Mead GP; Bradwell AR; Barnett AH
Expert Opin Ther Targets; 2008 Jun; 12(6):667-76. PubMed ID: 18479214
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.
Hutchison CA; Harding S; Hewins P; Mead GP; Townsend J; Bradwell AR; Cockwell P
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1684-90. PubMed ID: 18945993
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
4. Serum and urine free light chains measurements in patients with systemic sclerosis: novel biomarkers for disease activity.
Gigante A; Pellicano C; Leodori G; Napodano C; Vantaggio L; Gulli F; Marino M; Visentini M; Rosato E; Basile U
Clin Exp Immunol; 2021 Aug; 205(2):135-141. PubMed ID: 33934349
[TBL] [Abstract][Full Text] [Related]
5. Free Light Chains
Gudowska-Sawczuk M; Mroczko B
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298479
[TBL] [Abstract][Full Text] [Related]
6. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
7. Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.
Draborg AH; Lydolph MC; Westergaard M; Olesen Larsen S; Nielsen CT; Duus K; Jacobsen S; Houen G
PLoS One; 2015; 10(9):e0138753. PubMed ID: 26402865
[TBL] [Abstract][Full Text] [Related]
8. Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis.
Hanaoka M; Gono T; Kawaguchi Y; Uchida K; Koseki Y; Katsumata Y; Kaneko H; Takagi K; Ichida H; Nitta K; Yamanaka H
Rheumatology (Oxford); 2013 Dec; 52(12):2149-57. PubMed ID: 23463805
[TBL] [Abstract][Full Text] [Related]
9. Serum free light chains are reduced in endurance trained older adults: Evidence that exercise training may reduce basal inflammation in older adults.
Heaney JL; Phillips AC; Drayson MT; Campbell JP
Exp Gerontol; 2016 May; 77():69-75. PubMed ID: 26921802
[TBL] [Abstract][Full Text] [Related]
10. Urinary free light chains may help to identify infection in patients with elevated systemic inflammation due to rheumatic disease.
Bramlage CP; Froelich B; Wallbach M; Minguet J; Grupp C; Deutsch C; Bramlage P; Müller GA; Koziolek M
Rheumatol Int; 2017 Apr; 37(4):599-605. PubMed ID: 28214923
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of measurement of free light chains].
Matsuda M
Rinsho Byori; 2010 Apr; 58(4):401-4. PubMed ID: 20496770
[TBL] [Abstract][Full Text] [Related]
12. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
13. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.
Jeon YK; Kim MR; Huh JE; Mok JY; Song SH; Kim SS; Kim BH; Lee SH; Kim YK; Kim IJ
J Korean Med Sci; 2011 Feb; 26(2):258-63. PubMed ID: 21286018
[TBL] [Abstract][Full Text] [Related]
14. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies.
Hill PG; Forsyth JM; Rai B; Mayne S
Clin Chem; 2006 Sep; 52(9):1743-8. PubMed ID: 16858075
[TBL] [Abstract][Full Text] [Related]
15. Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities.
Napodano C; Pocino K; Gulli F; Rossi E; Rapaccini GL; Marino M; Basile U
Adv Clin Chem; 2022; 108():155-209. PubMed ID: 35659060
[TBL] [Abstract][Full Text] [Related]
16. The potential role of serum polyclonal free light chains as markers of immune activation in psoriatic patients.
Di Caprio R; Sacchelli L; Di Spigna G; Ricciardone M; Bardazzi F; Ladogana P; Scala E; Fabbrocini G; Covelli B; Balato A; Postiglione L
Eur J Dermatol; 2023 Feb; 33(1):12-18. PubMed ID: 37154810
[TBL] [Abstract][Full Text] [Related]
17. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
18. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy.
Fujita H; Morii T; Koshimura J; Ishikawa M; Kato M; Miura T; Sasaki H; Narita T; Ito S; Kakei M
Endocr J; 2006 Dec; 53(6):745-52. PubMed ID: 16966829
[TBL] [Abstract][Full Text] [Related]
19. Serum free light chain assessment in type 1 autoimmune pancreatitis.
Ikemune M; Uchida K; Tsukuda S; Ito T; Nakamaru K; Tomiyama T; Ikeura T; Naganuma M; Okazaki K
Pancreatology; 2021 Apr; 21(3):658-665. PubMed ID: 33741268
[TBL] [Abstract][Full Text] [Related]
20. Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals.
Shiels MS; Landgren O; Costello R; Zingone A; Goedert JJ; Engels EA
Clin Infect Dis; 2012 Nov; 55(10):e103-8. PubMed ID: 22893577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
